Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arvinas Inc (ARVN)

Arvinas Inc (ARVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,700,535
  • Shares Outstanding, K 68,432
  • Annual Sales, $ 78,500 K
  • Annual Income, $ -367,300 K
  • 60-Month Beta 1.98
  • Price/Sales 23.21
  • Price/Cash Flow N/A
  • Price/Book 2.98
Trade ARVN with:

Options Overview Details

View History
  • Implied Volatility 80.62% ( +9.42%)
  • Historical Volatility 65.30%
  • IV Percentile 88%
  • IV Rank 35.95%
  • IV High 125.27% on 11/13/23
  • IV Low 55.56% on 09/19/23
  • Put/Call Vol Ratio 0.01
  • Today's Volume 191
  • Volume Avg (30-Day) 276
  • Put/Call OI Ratio 0.15
  • Today's Open Interest 4,100
  • Open Int (30-Day) 4,944

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.72
  • Number of Estimates 11
  • High Estimate 1.09
  • Low Estimate -1.43
  • Prior Year -1.25
  • Growth Rate Est. (year over year) +42.40%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.73 +0.72%
on 06/25/24
30.12 -20.65%
on 06/05/24
-3.99 (-14.31%)
since 06/03/24
3-Month
23.73 +0.72%
on 06/25/24
39.40 -39.34%
on 04/04/24
-14.69 (-38.07%)
since 04/03/24
52-Week
13.57 +76.12%
on 10/27/23
53.08 -54.97%
on 02/16/24
-1.28 (-5.08%)
since 07/03/23

Most Recent Stories

More News
As Early-Onset Breast Cancer Cases Soar in North America and EU, Biotech Ramps Up Response

/CNW/ -- USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In...

ONCY : 1.0100 (+2.02%)
ICCM : 0.7393 (-0.27%)
ATOS : 1.1700 (+0.86%)
ARVN : 23.90 (-3.82%)
PFE : 27.70 (-0.47%)
ONC.TO : 1.41 (+2.92%)
Biotech Firms Intensify Efforts as Breast Cancer Strikes Younger Patients at Alarming Rate

USA News Group – An alarming rise in early-onset cancers has medical experts very concerned, as cancer cases in younger people are rising sharply. In particular, a surge in cases of breast cancer is...

ONCY : 1.0100 (+2.02%)
ONC.TO : 1.41 (+2.92%)
ICCM : 0.7393 (-0.27%)
ATOS : 1.1700 (+0.86%)
ARVN : 23.90 (-3.82%)
PFE : 27.70 (-0.47%)
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer

USA News Group – More people are getting breast cancer this year. Around 300,000 women and 2,800 men will find out they have it. While 1 out of every 8 women will hear they have breast cancer sometime...

ONCY : 1.0100 (+2.02%)
ONC.TO : 1.41 (+2.92%)
PFE : 27.70 (-0.47%)
ARVN : 23.90 (-3.82%)
OLMA : 10.67 (+2.50%)
AZN : 76.80 (-0.25%)
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer

USA News Group – More people are getting breast cancer this year. Around 300,000 women and 2,800 men will find out they have it. While 1 out of every 8 women will hear they have breast cancer sometime...

AVRN : 0.0125 (-30.56%)
ONCY : 1.0100 (+2.02%)
ONC.TO : 1.41 (+2.92%)
PFE : 27.70 (-0.47%)
ARVN : 23.90 (-3.82%)
OLMA : 10.67 (+2.50%)
AZN : 76.80 (-0.25%)
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial

/PRNewswire/ -- Arvinas, Inc. (Nasdaq: ARVN) and Quantum Leap Healthcare Collaborative™ today announced that Arvinas' vepdegestrant (ARV-471), a novel PROTAC®...

ARVN : 23.90 (-3.82%)
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023

Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.

ARVN : 23.90 (-3.82%)
RCKT : 20.03 (+1.26%)
XNCR : 18.61 (+1.92%)
Jon Soderstrom Joins Wilson Sonsini as Chief Licensing Advisor

Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jon Soderstrom is joining the firm as its chief...

ACHN : 0.7912 (-21.66%)
ARVN : 23.90 (-3.82%)
NXTC : 1.5700 (+4.67%)
BHVN : 33.79 (-1.11%)
INZY : 4.49 (+1.58%)
Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...

ARVN : 23.90 (-3.82%)
Arvinas Appoints John Northcott as Chief Commercial Officer

NEW HAVEN, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...

ARVN : 23.90 (-3.82%)
Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference

NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs...

ARVN : 23.90 (-3.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

See More Share

Business Summary

Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.

See More

Key Turning Points

3rd Resistance Point 26.18
2nd Resistance Point 25.67
1st Resistance Point 24.78
Last Price 23.90
1st Support Level 23.38
2nd Support Level 22.87
3rd Support Level 21.98

See More

52-Week High 53.08
Fibonacci 61.8% 37.99
Fibonacci 50% 33.33
Fibonacci 38.2% 28.66
Last Price 23.90
52-Week Low 13.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar